Medigen Vaccine Biologics Corp. (6547) AI Stock Analysis

Medigen Vaccine Biologics Corp.

(TPEx:6547)

Select Model

Rating:42Neutral

Price Target:TWD 45.00▼(-2.91% Downside)

Action:initiatedcoverage

Date:11/10/26

Weak profitability and negative cash flow are the primary risks, despite a strong, lightly leveraged balance sheet. Technical momentum is also weak, while the negative P/E and absence of dividend support further constrain the score.

Positive Factors

Low LeverageThe conservative capital structure gives Medigen more financial flexibility than a highly leveraged biotechnology company. Low debt relative to equity can reduce refinancing pressure and preserve capacity to fund vaccine development, manufacturing, and commercialization initiatives.

Negative Factors

Persistent LossesPersistent losses and a negative EBITDA position show that the current business model has not yet converted its vaccine and biologics activities into sustainable operating earnings. Continued losses can limit internal funding capacity and increase dependence on future financing or successful product execution.

Medigen Vaccine Biologics Corp. (6547) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 15.40B
Dividend Yield: ―
Average Volume (3M): 4.22M
Price to Earnings (P/E): -409.9
Beta (1Y): 0.27
Revenue Growth: 44.37%
EPS Growth: 78.11%
Country: TW
Employees: 1,226
Sector: General
Sector Strength: 55
Industry: Biotechnology

Medigen Vaccine Biologics Corp. Business Overview & Revenue Model

Company Description

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III cli...

Medigen Vaccine Biologics Corp. Financial Statement Overview

Summary

Strong balance sheet quality is outweighed by materially weaker profitability and cash flow. Revenue grew slightly, but margins declined, losses widened, and operating and free cash flow turned negative.

Income Statement

24Negative

Balance Sheet

78Positive

Cash Flow

29Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	573.85M	613.17M	605.64M	389.62M	365.04M	3.28B
Gross Profit	346.82M	364.67M	396.42M	230.22M	-212.60M	2.31B
EBITDA	-12.24M	-123.90M	74.86M	-991.09M	-1.32B	1.53B
Net Income	-166.77M	-281.71M	-80.47M	-1.16B	-1.50B	1.41B
Balance Sheet
Total Assets	4.76B	3.93B	4.36B	6.09B	7.35B	5.30B
Cash, Cash Equivalents and Short-Term Investments	2.04B	1.78B	1.92B	3.76B	4.24B	2.23B
Total Debt	1.10B	283.44M	338.96M	1.97B	1.98B	187.58M
Total Liabilities	1.21B	454.64M	513.92M	2.25B	2.32B	622.95M
Stockholders Equity	3.56B	3.48B	3.85B	3.85B	5.03B	4.68B
Cash Flow
Free Cash Flow	-217.55M	-99.72M	5.77M	-519.29M	-1.24B	444.92M
Operating Cash Flow	-55.34M	-49.09M	40.75M	-478.33M	-1.10B	579.89M
Investing Cash Flow	-573.52M	-35.30M	1.02B	669.83M	-2.40B	-930.69M
Financing Cash Flow	767.65M	-39.19M	-1.74B	1.59M	3.32B	51.18M

Medigen Vaccine Biologics Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6547 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4114	61Neutral	TWD 14.97B	17.66	―	3.06%	11.40%	9.36%
TW:1789	57Neutral	TWD 16.01B	904.98	―	1.45%	-4.75%	-90.91%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4147	47Neutral	TWD 16.47B	-103.67	―	―	7.02%	25.72%
TW:6547	42Neutral	TWD 16.94B	-409.93	―	―	44.37%	78.11%

* General Sector Average

Performance Comparison

TW:6547 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6547	Medigen Vaccine Biologics Corp.	46.35	8.95	23.93%
TW:1789	Scinopharm Taiwan, Ltd.	20.00	2.60	14.92%
TW:4114	Synmosa Biopharma Corp	27.75	-1.94	-6.53%
TW:4147	TaiMed Biologics Inc.	61.90	-6.60	-9.64%
TW:6586	CHO Pharma, Inc.	76.20	46.15	153.58%
TW:6589	EirGenix, Inc.	51.70	-30.20	-36.87%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Medigen Vaccine Biologics Corp. AI Stock Analysis